These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1999719)

  • 1. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
    Scheinberg DA; Lovett D; Divgi CR; Graham MC; Berman E; Pentlow K; Feirt N; Finn RD; Clarkson BD; Gee TS
    J Clin Oncol; 1991 Mar; 9(3):478-90. PubMed ID: 1999719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
    Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
    Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
    Schwartz MA; Lovett DR; Redner A; Finn RD; Graham MC; Divgi CR; Dantis L; Gee TS; Andreeff M; Old LJ
    J Clin Oncol; 1993 Feb; 11(2):294-303. PubMed ID: 8426207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
    Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
    Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
    Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
    Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.
    Tanimoto M; Scheinberg DA; Cordon-Cardo C; Huie D; Clarkson BD; Old LJ
    Leukemia; 1989 May; 3(5):339-48. PubMed ID: 2716349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
    Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
    Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ
    J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.
    Scheinberg DA; Tanimoto M; McKenzie S; Strife A; Old LJ; Clarkson BD
    Leukemia; 1989 Jun; 3(6):440-5. PubMed ID: 2725060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
    Badger CC; Davis J; Nourigat C; Wu ZM; Hui TE; Fisher DR; Shulman H; Appelbaum FR; Eary JF; Krohn KA
    Cancer Res; 1991 Nov; 51(21):5921-8. PubMed ID: 1682038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
    Caron PC; Dumont L; Scheinberg DA
    Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
    Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
    Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.